Literature DB >> 26733165

Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer.

Rong-Liang Shi1,2,3, Ning Qu1,2, Tian Liao1,2, Wen-Jun Wei1,2, Zhong-Wu Lu1,2, Ben Ma1,2, Yu-Long Wang4,5, Qing-Hai Ji6,7.   

Abstract

Current evidences suggest an influence of overweight body mass index (BMI) on the carcinogenesis in malignancies. However, the role of BMI is unclear in papillary thyroid cancer (PTC). The aim of the present study is to investigate the relationship between BMI and BRAF (V600E) mutation status in PTC. BRAF (V600E) mutation in 108 patients with PTC was analyzed by Sanger sequencing. The cutoff point of BMI was identified by X-tile for predicting mutation by overweight. Odds ratios (OR) and 95 % confidence interval (CI) of BRAF (V600E) mutation according to BMI and clinicopathologic variables were calculated using logistic regression models. Fifty-one patients were positive for BRAF (V600E) mutation. A positive relationship existed between BRAF (V600E) mutation and BMI (p = 0.039). A 24.3 kg/m(2) was identified as cutoff point for differentiating greater than 52.0 % observed probability of mutation for BRAF (V600E) in entire cohort, which was similar to the midpoint between the upper limit of normal BMI and overweight defined by WHO (≥24 kg/m(2)). Multivariate analysis confirmed the association between BRAF (V600E) mutation with overweight BMI range (OR 7.645, 95 % CI 1.275-45.831, p = 0.026). This study suggests an influence of overweight BMI on the status of BRAF (V600E) in patients with PTC, whereas the underlying mechanism need to be further investigated.

Entities:  

Keywords:  BRAF mutation; Body mass index; Overweight; Papillary thyroid cancer

Mesh:

Substances:

Year:  2016        PMID: 26733165     DOI: 10.1007/s13277-015-4718-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  Bmi-1, c-myc, and Snail expression in primary breast cancers and their metastases--elevated Bmi-1 expression in late breast cancer relapses.

Authors:  Kristiina Joensuu; Jaana Hagström; Marjut Leidenius; Caj Haglund; Leif C Andersson; Hannu Sariola; Päivi Heikkilä
Journal:  Virchows Arch       Date:  2011-06-03       Impact factor: 4.064

2.  Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer.

Authors:  Bun Kim; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Won Ho Kim; Sung Pil Hong
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; Young Kee Shong; Tae Yong Kim; David Viola; Rossella Elisei; Bela Bendlová; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Roderick Clifton-Bligh; Giovanni Tallini; Elizabeth H Holt; Vlasta Sýkorová
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

4.  Adult BMI change and risk of Breast Cancer: National Health and Nutrition Examination Survey (NHANES) 2005-2010.

Authors:  Wambui G Gathirua-Mwangi; Terrell W Zollinger; Mwangi J Murage; Kamnesh R Pradhan; Victoria L Champion
Journal:  Breast Cancer       Date:  2015-09-08       Impact factor: 4.239

5.  Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer.

Authors:  Martha L Slattery; Karen Curtin; Carol Sweeney; Theodore R Levin; John Potter; Roger K Wolff; Hans Albertsen; Wade S Samowitz
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

6.  Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer.

Authors:  Haixia Guan; Meiju Ji; Peng Hou; Zhi Liu; Cuifang Wang; Zhongyan Shan; Weiping Teng; Mingzhao Xing
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

Review 7.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

8.  BRAF V600E mutation and papillary thyroid cancer.

Authors:  Mingzhao Xing
Journal:  JAMA       Date:  2013-08-07       Impact factor: 56.272

9.  BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management.

Authors:  Mingzhao Xing
Journal:  Ann Surg Oncol       Date:  2009-01-22       Impact factor: 5.344

10.  European Code against Cancer 4th Edition: Obesity, body fatness and cancer.

Authors:  Annie S Anderson; Timothy J Key; Teresa Norat; Chiara Scoccianti; Michele Cecchini; Franco Berrino; Marie-Christine Boutron-Ruault; Carolina Espina; Michael Leitzmann; Hilary Powers; Martin Wiseman; Isabelle Romieu
Journal:  Cancer Epidemiol       Date:  2015-07-21       Impact factor: 2.984

View more
  4 in total

1.  The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.

Authors:  Subramaniam Ramkumar; Shanthakumari Sivanandham
Journal:  Cureus       Date:  2021-12-10

2.  Influence of Nomenclature Changes on Trends in Papillary Thyroid Cancer Incidence in the United States, 2000 to 2017.

Authors:  Cari M Kitahara; Julie A Sosa; Meredith S Shiels
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

3.  Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.

Authors:  Lihua Huang; Xuming Wang; Xuan Huang; Huawei Gui; Yan Li; Qiongxia Chen; Dongling Liu; Lijiang Liu
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

4.  Effect of MALAT1 Polymorphisms on Papillary Thyroid Cancer in a Chinese Population.

Authors:  Jing Wen; Liang Chen; Hua Tian; Ji Li; Miao Zhang; Qing Cao; Wei Zhang; Shi Chen; Lixin Shi
Journal:  J Cancer       Date:  2019-09-19       Impact factor: 4.207

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.